Continuous Glucose Monitoring in the Intensive Care Unit
Traditionally, the care of critically ill patients with diabetes or stress hyperglycemia in the intensive care unit (ICU) demands the use of continuous intravenous insulin (CII) therapy to achieve narrow glycemic targets. To reduce the risk of iatrogenic hypoglycemia and to achieve glycemic targets during CII, healthcare providers (HCP) rely on hourly point-of-care (POC) arterial or capillary glucose tests obtained with glucose monitors. The burden of this approach, however, was evident during the beginning of the pandemic when the immediate reduction in close contact interactions between HCP and patients with COVID-19 was necessary to avoid potentially life-threatening exposures. Taking advantage of the advancements in current diabetes technologies, including continuous glucose monitoring (CGM) devices integrated with digital health tools for remote monitoring, HCP implemented novel protocols in the ICU to care for patients with COVID-19 and hyperglycemia. We provide an overview of research conducted in the ICU setting with the use of initial CGM technology to current devices and summarize our recent experience in the ICU.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Journal of diabetes science and technology - 17(2023), 3 vom: 20. Mai, Seite 667-678 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guerrero-Arroyo, Lizda [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood Glucose |
|---|
| Anmerkungen: |
Date Completed 03.05.2023 Date Revised 21.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/19322968231169522 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355856131 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355856131 | ||
| 003 | DE-627 | ||
| 005 | 20240421231926.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/19322968231169522 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1382.xml |
| 035 | |a (DE-627)NLM355856131 | ||
| 035 | |a (NLM)37081830 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guerrero-Arroyo, Lizda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Continuous Glucose Monitoring in the Intensive Care Unit |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.05.2023 | ||
| 500 | |a Date Revised 21.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Traditionally, the care of critically ill patients with diabetes or stress hyperglycemia in the intensive care unit (ICU) demands the use of continuous intravenous insulin (CII) therapy to achieve narrow glycemic targets. To reduce the risk of iatrogenic hypoglycemia and to achieve glycemic targets during CII, healthcare providers (HCP) rely on hourly point-of-care (POC) arterial or capillary glucose tests obtained with glucose monitors. The burden of this approach, however, was evident during the beginning of the pandemic when the immediate reduction in close contact interactions between HCP and patients with COVID-19 was necessary to avoid potentially life-threatening exposures. Taking advantage of the advancements in current diabetes technologies, including continuous glucose monitoring (CGM) devices integrated with digital health tools for remote monitoring, HCP implemented novel protocols in the ICU to care for patients with COVID-19 and hyperglycemia. We provide an overview of research conducted in the ICU setting with the use of initial CGM technology to current devices and summarize our recent experience in the ICU | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CGM | |
| 650 | 4 | |a continuous glucose monitoring | |
| 650 | 4 | |a critically ill | |
| 650 | 4 | |a hospital | |
| 650 | 4 | |a inpatient | |
| 650 | 4 | |a intensive care unit | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 650 | 7 | |a Insulin, Regular, Human |2 NLM | |
| 700 | 1 | |a Faulds, Eileen |e verfasserin |4 aut | |
| 700 | 1 | |a Perez-Guzman, M Citlalli |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Georgia M |e verfasserin |4 aut | |
| 700 | 1 | |a Dungan, Kathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Pasquel, Francisco J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of diabetes science and technology |d 2007 |g 17(2023), 3 vom: 20. Mai, Seite 667-678 |w (DE-627)NLM179163914 |x 1932-2968 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:3 |g day:20 |g month:05 |g pages:667-678 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/19322968231169522 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 3 |b 20 |c 05 |h 667-678 | ||